A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. (Q36979082)
Jump to navigation
Jump to search
scientific article published on 26 July 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. |
scientific article published on 26 July 2010 |
Statements
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model (English)
N V Rajeshkumar
Zeshaan A Rasheed
Elena García-García
Fernando López-Ríos
Kosaku Fujiwara
1 reference
1 reference